Navigation Links
Cadence Pharmaceuticals Updates Omigard(TM) Clinical Timeline
Date:9/15/2008

SAN DIEGO, Sept. 15 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) announced today that it has revised the expected timing of its announcement of results for the CLIRS trial, the company's Phase III clinical trial of Omigard(TM) (omiganan pentahydrochloride 1% topical gel) for the prevention of catheter-related infections.

Cadence is currently engaged in discussions with the U.S. Food and Drug Administration (FDA) regarding the statistical analysis plan for the CLIRS trial. These discussions, which are being conducted under a Special Protocol Assessment (SPA), must be completed prior to unblinding the data from the trial. As a result, Cadence has revised the expected timing of its announcement of results for the CLIRS trial from the fourth quarter of 2008 to the first quarter of 2009. If the trial is successful, Cadence continues to plan for submission of a New Drug Application (NDA) for Omigard in the second quarter of 2009.

About the CLIRS trial

The CLIRS trial, or Central Line Infection Reduction Study, is Cadence's confirmatory Phase III clinical trial of Omigard(TM) for the prevention of catheter-related infections. The CLIRS trial is a multi-center, randomized, evaluation committee-blinded study in patients whose medical condition requires a central venous catheter. The primary efficacy endpoint of the clinical trial is to evaluate whether Omigard is superior to 10% povidone-iodine in the prevention of local catheter-site infections. The CLIRS trial, which has completed enrollment of over 1,850 patients randomized to receive either Omigard or 10% povidone-iodine, is designed to have 80% power to detect significance at the 0.05 level. The CLIRS trial is being conducted under an SPA with th
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results and Provide a Clinical Program Update on August 7, 2008
2. Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
3. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
4. VIA Pharmaceuticals to Present at American Heart Association Scientific Sessions 2008
5. Unibioscreen and Drais Pharmaceuticals Partner to Develop and Commercialize UNBS 5162 for Treatment of Cancer
6. Vanda Pharmaceuticals Provides Update on Iloperidone
7. Cerimon Pharmaceuticals Announces Positive Results from a Phase II Clinical Study of Its Diclofenac Sodium Patch for Acute Pain
8. Jazz Pharmaceuticals, Inc. Announces Final Patient Has Completed Phase III Clinical Trial of Sodium Oxybate to Treat Fibromyalgia
9. Addrenex Pharmaceuticals Announces Positive Phase III Clinical Results for Clonicel to Treat ADHD
10. Celator Pharmaceuticals Receives Orphan Drug Designation for Anticancer Agent CPX-351
11. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... WASHINGTON , Feb. 26, 2015  Mail-service ... consumers, employers and government health plans ... research released by the Pharmaceutical Care Management Association ... specialty drugs offers one of the easiest ways ... CEO Mark Merritt . "Policymakers should resist ...
(Date:2/26/2015)... 2015 Every year many millions of donations ... disease.  Nevertheless, year after year doctors and the medical ... first test to determine the status of heart health ... not, even though that technology is over 100 years ... doctors know, (while most patients do not know) that ...
(Date:2/26/2015)... DUBLIN , Feb. 26, 2015 Research and ... addition of the "Radiation Therapy Equipment - Global ... This report analyzes the worldwide markets for ... Product Segments: Linear Accelerator, Treatment Planning Systems, and Radiation ... the US, Canada , ...
Breaking Medicine Technology:PCMA: Report Shows High-Tech Specialty and Mail-Service Pharmacies Will Reduce Costs for Texas Employers, Consumers and Public Programs by $23.3 Billion 2National Heart Health Month In February 2Radiation Therapy Equipment - Global Strategic Business Report 2015-2020: Linear Accelerator, Treatment Planning Systems, and Radiation Therapy Simulator 2
(Date:2/27/2015)... 27, 2015 Today, February 27th, is "Shine ... , along with LXR Organics and Living ... Campaign to raise awareness and promote prevention, rescue and restoration ... by the END IT Coalition, slavery is the 2nd largest ... exists in 167 countries around the world. Slavery includes bonded ...
(Date:2/27/2015)... CA (PRWEB) February 27, 2015 Pipette.com ... Vortex-Genie® 2 , price is only valid until the ... lab technicians looking for a vortex mixer that allows ... Industries was founded in 1954 and is headquartered in ... mixers & shakers, as well as other rockers, incubators, ...
(Date:2/27/2015)... February 27, 2015 The federal court ... that allege use of the statin medication can increase ... issued a new order pertaining discovery in the cases ... Liebhard LLP comments. The Order, which was issued in ... February 25th, directs the parties to schedule certain witness ...
(Date:2/27/2015)... Legislation passed today by the ... provision to help prevent inappropriate prescriptions in Medicare ... Protecting the Integrity of Medicare Act (PIMA), introduced ... Brady (R-TX) and Ranking Member Jim McDermott (D-WA), ... abuse epidemic and implement the right policies, said ...
(Date:2/27/2015)... Victorian Hotel recently celebrated Valentine’s Day in ... to spend the auspicious day together. This Vancouver hotel ... on Valentine’s Day with a sweet overnight package, including ... luxurious rooms. , The hotel started its Valentine’s ... mouthwatering 3 course meal at Café 335. This is ...
Breaking Medicine News(10 mins):Health News:KAJ Brothers Join the Campaign to 'End It - Shine A Light On Slavery' 2Health News:Pipette.com Announces Limited Time Offer of 24% Off List Price on the Vortex-Genie 2 2Health News:Federal Lipitor Litigation Issues New Order Pertaining to Discovery in Bellwether Cases, Bernstein Liebhard LLP Comments 2Health News:Federal Lipitor Litigation Issues New Order Pertaining to Discovery in Bellwether Cases, Bernstein Liebhard LLP Comments 3Health News:PCMA Statement on the ‘Protecting the Integrity of Medicare Act’ 2Health News:Victorian Hotel Celebrated Valentine’s Day in 2015 With Unique Overnight Deal 2
... launches $20,000 Nationwide Scholarship, Competition with Celebrity Spokesperson Megyn Price of ... ... NEW YORK, May 9 The Tea Council of the USA,Inc. ... scholarship competition awarding one creative student $20,000,towards their education, in an ...
... Daisy Fuentes in honoring Emilio and Gloria Estefan at the event to ... ... Luis Fonsi, Jeremias, and Valeria Gastaldi, MIAMI, May 9 St. ... its sixth annual FedEx/St. Jude Angels & Stars Gala on Saturday,May 17, ...
... 9 Oceana, an international,ocean conservation group based in ... many years. Consuming big fish high on,the food chain ... mercury, a heavy,metal that can cause neurological and other ... celebrity spokes-Mom Amber Valletta,offers a few tips for keeping ...
... 9 VNUS(R) Medical,Technologies, Inc. today announced that the ... second continuation patent application related to,the patents in the ... This comes on the heels of the Patent Office,s,decision ... also filed,as a continuation of one of the patents ...
... of infected patients in U.K., researchers say , , ... Steno, one the most recent "superbugs" to claim lives, ... resist antibiotics and other drugs, according to soon-to-be-published findings. ... thrives in moist environments, such as around taps and ...
... Remain Stable or Improve in 86% at Six Months, ... NDQ), a developer of real-time imaging and image guidance ... independent data was,presented at the recent Association for Research ... April 26 - May,1, 2008. Data from two of ...
Cached Medicine News:Health News:Drink Tea. Win $20,000. Experience the 'Calm-A-Sutra of Tea' 2Health News:Drink Tea. Win $20,000. Experience the 'Calm-A-Sutra of Tea' 3Health News:Miami Rolls Out the Red Carpet for Latin Star Studded FedEx/St. Jude Gala 2Health News:Miami Rolls Out the Red Carpet for Latin Star Studded FedEx/St. Jude Gala 3Health News:Amber Valletta on Preventing Mercury Exposure 2Health News:Amber Valletta on Preventing Mercury Exposure 3Health News:U.S. Patent Office Allows Another Significant VNUS Patent 2Health News:U.S. Patent Office Allows Another Significant VNUS Patent 3Health News:Steno 'Superbug' Genome Shows Extreme Drug Resistance 2Health News:Novadaq's OPTTX System Data Presented at ARVO 2Health News:Novadaq's OPTTX System Data Presented at ARVO 3Health News:Novadaq's OPTTX System Data Presented at ARVO 4
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: